Patients with metastatic or recurrent gastric cancer refractory to S-1-based first-line chemotherapy were randomly assigned to receive BIRIP ( irinotecan 60mg/m ( 2 ) plus cisplatin 30mg/m ( 2 ) , every 2weeks ) or irinotecan alone ( irinotecan 150mg/m ( 2 ) , every 2weeks ) .